A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Attention-deficit hyperactivity disorder (ADHD) is a common neuropsychiatric disorder that is often diagnosed during childhood, but has also increasingly been recognized to occur in adults. Importantly, up to 52% of children (including adolescents) and 87% of adults with ADHD also have a comorbid psychiatric disorder. The presence of a comorbid disorder has the potential to impact diagnosis and could affect treatment outcomes. Atomoxetine is a nonstimulant treatment for ADHD. Despite numerous published studies regarding efficacy of atomoxetine in the treatment of ADHD in patients with comorbid disorders, there is limited information about the impact of individual common comorbid disorders on the efficacy of atomoxetine for ADHD, especially with regard to adults. Moreover, a cumulative review and assessment of these studies has not been conducted. For this reason, we performed a literature review to find, identify, and cumulatively review clinical studies that examined the efficacy of atomoxetine in the treatment of patients with ADHD and comorbid psychiatric disorders. We found a total of 50 clinical studies (37 in children; 13 in adults) that examined the efficacy of atomoxetine in patients with ADHD and a comorbid disorder. The comorbidities that were studied in children or in adults included anxiety, depression, and substance use disorder. Overall, the presence of comorbidity did not adversely impact the efficacy of atomoxetine in treatment of ADHD symptoms in both patient populations. In the studies identified and assessed in this review, atomoxetine did not appear to exacerbate any of the comorbid conditions and could, therefore, be an important therapy choice for the treatment of ADHD in the presence of comorbid disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Adler, L., Barkley, R., Biederman, J., Conners, C. K., Demler, O., Faraone, S. V., Greenhill, L. L., Howes, M. J., Secnik, K., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.716 · Cited by 3,886 · cited 2×
“Although depression with ADHD is a common occurrence, 9,28 we found only 2 RCTs on atomoxetine in adults with ADHD and depression (Table 5).”
FARAONE, S. V., BIEDERMAN, J., & MICK, E. (2006) · Psychological Medicine · doi:10.1017/s003329170500471x · Cited by 2,267
Subcommittee on Attention-Deficit/Hyperactivity Disorder, S. C. O. Q. I. A. M. (2011) · Pediatrics · doi:10.1542/peds.2011-2654 · Cited by 2,185
The Prevalence of DSM-IV Attention-Deficit/Hyperactivity Disorder: A Meta-Analytic Review
Willcutt, E. G. (2012) · Neurotherapeutics · doi:10.1007/s13311-012-0135-8 · Cited by 2,160
Pliszka, S. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318054e724 · Cited by 1,765
Patterns of Comorbidity, Functioning, and Service Use for US Children With ADHD, 2007
Larson, K., Russ, S. A., Kahn, R. S., & Halfon, N. (2011) · Pediatrics · doi:10.1542/peds.2010-0165 · Cited by 580
Jensen, C. M., & Steinhausen, H.-C. (2015) · ADHD Attention Deficit and Hyperactivity Disorders · doi:10.1007/s12402-014-0142-1 · Cited by 402
Garnock-Jones, K. P., & Keating, G. M. (2009) · Pediatric Drugs · doi:10.2165/00148581-200911030-00005 · Cited by 392
Cortese, S., Holtmann, M., Banaschewski, T., Buitelaar, J., Coghill, D., Danckaerts, M., Dittmann, R. W., Graham, J., Taylor, E., Sergeant, J., et al. (2013) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12036 · Cited by 336
Bolea-Alamañac, B., Nutt, D. J., Adamou, M., Asherson, P., Bazire, S., Coghill, D., Heal, D., Müller, U., Nash, J., Santosh, P., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113519509 · Cited by 287
Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial
ARNOLD, L. E., AMAN, M. G., COOK, A. M., WITWER, A. N., HALL, K. L., THOMPSON, S., & RAMADAN, Y. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000231976.28719.2a · Cited by 260
Effects of Atomoxetine and Methylphenidate on Sleep in Children With ADHD
Sangal, R. B., Owens, J., Allen, A. J., Sutton, V., Schuh, K., & Kelsey, D. (2006) · Sleep · doi:10.1093/sleep/29.12.1573 · Cited by 214
Impact of Comorbid Oppositional or Conduct Problems on Attention-Deficit Hyperactivity Disorder
KUHNE, M., SCHACHAR, R., & TANNOCK, R. (1997) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199712000-00020 · Cited by 209 · cited 1×
“50,94 A total of 14 studies were found addressing the use of atomoxetine in this patient population (Table 4).”
Developmental comorbidity in attention-deficit/hyperactivity disorder
Taurines, R., Schmitt, J., Renner, T., Conner, A. C., Warnke, A., & Romanos, M. (2010) · ADHD Attention Deficit and Hyperactivity Disorders · doi:10.1007/s12402-010-0040-0 · Cited by 198 · cited 15×
“45 Because of the high incidence of psychiatric comorbidities in patients with ADHD, an alternative to stimulants that may be contraindicated due to comorbidities could be warranted in some cases.”
InfluentialThe Potential for Misuse and Abuse of Medications in ADHD: A Review
Clemow, D. B., & Walker, D. J. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.09.2801 · Cited by 198
Self-citationCheng, J. Y. W., Chen, R. Y. L., Ko, J. S. N., & Ng, E. M. L. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0840-x · Cited by 185 · cited 9×
“Whereas some of these conditions are subjected to rigorous placebo-controlled, double-blind RCTs, some, such as ODD, are lacking in such studies because individuals with these comorbidities are often excluded from ADHD clinical trials.”
InfluentialAdler, L. A., Liebowitz, M., Kronenberger, W., Qiao, M., Rubin, R., Hollandbeck, M., Deldar, A., Schuh, K., & Durell, T. (2009) · Depression and Anxiety · doi:10.1002/da.20549 · Cited by 176
Newcorn, J. H., Spencer, T. J., Biederman, J., Milton, D. R., & Michelson, D. (2005) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200503000-00008 · Cited by 174
Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders
Wilens, T. E., Adler, L. A., Weiss, M. D., Michelson, D., Ramsey, J. L., Moore, R. J., Renard, D., Brady, K. T., Trzepacz, P. T., Schuh, L. M., et al. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.02.009 · Cited by 171
Harfterkamp, M., van de Loo-Neus, G., Minderaa, R. B., van der Gaag, R.-J., Escobar, R., Schacht, A., Pamulapati, S., Buitelaar, J. K., & Hoekstra, P. J. (2012) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2012.04.011 · Cited by 171 · cited 1×
“69 However, extending the time-course of atomoxetine administration resulted in continued improvement in ADHD symptoms, suggesting that more time is needed for the full effects of atomoxetine to become established in patients with ADHD and ASD.”
Wingo, A. P., & Ghaemi, S. N. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1118 · Cited by 160 · cited 1×
“27 In spite of these estimates, there are few studies on the treatment of individuals with ADHD and bipolar disorder.”
Kratochvil, C. J., Newcorn, J. H., Arnold, L. E., Duesenberg, D., Emslie, G. J., Quintana, H., Sarkis, E. H., Wagner, K. D., Gao, H., & Michelson, D. (2005) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000169012.81536.38 · Cited by 152 · cited 3×
“46 In an open-label study, atomoxetine improved ADHD symptoms, and symptoms of depression were improved in 55% of the patients.”
Meta-Analysis of Suicide-Related Behavior Events in Patients Treated With Atomoxetine
BANGS, M. E., TAUSCHER-WISNIEWSKI, S., POLZER, J., ZHANG, S., ACHARYA, N., DESAIAH, D., TRZEPACZ, P. T., & ALLEN, A. J. (2008) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e31815d88b2 · Cited by 152
Reichow, B., Volkmar, F. R., & Bloch, M. H. (2013) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-013-1793-z · Cited by 134
Posey, D. J., Wiegand, R. E., Wilkerson, J., Maynard, M., Stigler, K. A., & McDougle, C. J. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.599 · Cited by 117
McIntyre, R. S., Kennedy, S. H., Soczynska, J. K., Nguyen, H. T. T., Bilkey, T. S., Woldeyohannes, H. O., Nathanson, J. A., Joshi, S., Cheng, J. S. H., Benson, K. M., et al. (2010) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.09m00861gry · Cited by 103 · cited 1×
“102 In comorbid patients treated with atom-oxetine, it is likely that reported improvements in depressive symptoms result from an improvement in ADHD, and not from a direct antidepressant effect of atomoxetine.”
The Atomoxetine ADHD and Comorbid MDD Study Group:, Bangs, M. E., Emslie, G. J., Spencer, T. J., Ramsey, J. L., Carlson, C., Bartky, E. J., Busner, J., Duesenberg, D. A., Harshawat, P., et al. (2007) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2007.0066 · Cited by 103
Comparison of the burden of illness for adults with ADHD across seven countries: a qualitative study
Brod, M., Pohlman, B., Lasser, R., & Hodgkins, P. (2012) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-10-47 · Cited by 102
Atomoxetine Treatment of ADHD in Children With Comorbid Tourette Syndrome
Spencer, T. J., Sallee, F. R., Gilbert, D. L., Dunn, D. W., McCracken, J. T., Coffey, B. J., Budman, C. L., Ricardi, R. K., Leonard, H. L., Allen, A. J., et al. (2008) · Journal of Attention Disorders · doi:10.1177/1087054707306109 · Cited by 98
Thurstone, C., Riggs, P. D., Salomonsen-Sautel, S., & Mikulich-Gilbertson, S. K. (2010) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2010.02.013 · Cited by 96
Coughlin, C. G., Cohen, S. C., Mulqueen, J. M., Ferracioli-Oda, E., Stuckelman, Z. D., & Bloch, M. H. (2015) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2015.0075 · Cited by 86 · cited 1×
“3,34 Suicidal ideation is a symptom that may be present in ADHD patients with comorbid psychiatric disorders, especially depression and bipolar disorder.”
Bangs, M. E., Hazell, P., Danckaerts, M., Hoare, P., Coghill, D. R., Wehmeier, P. M., Williams, D. W., Moore, R. J., Levine, L., & for the Atomoxetine ADHD/ODD Study Group (2008) · Pediatrics · doi:10.1542/peds.2006-1880 · Cited by 79
The Complexity of ADHD: Diagnosis and Treatment of the Adult Patient With Comorbidities
Newcorn, J. H., Weiss, M., & Stein, M. A. (2007) · CNS Spectrums · doi:10.1017/s1092852900026158 · Cited by 66
Durell, T. M., Adler, L. A., Williams, D. W., Deldar, A., McGough, J. J., Glaser, P. E., Rubin, R. L., Pigott, T. A., Sarkis, E. H., & Fox, B. K. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31827d8a23 · Cited by 64 · cited 1×
“85,86 Substance use disorders The presence of SUD in patients with ADHD is an important clinical concern, occurring up to 4 times the incidence observed in individuals without ADHD.”
Wietecha, L., Williams, D., Shaywitz, S., Shaywitz, B., Hooper, S. R., Wigal, S. B., Dunn, D., & McBurnett, K. (2013) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2013.0054 · Cited by 58 · cited 1×
“64 While there was a positive correlation (correlation coefficient of 0.40–0.54, P 0.001, for K-SCT Parent subscale score with changes in Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent-Version:Investigator-Administered and Scored [ADHDRS-IV-Parent:Inv] scores; correlation…”
InfluentialChang, K., Nayar, D., Howe, M., & Rana, M. (2009) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2009.0030 · Cited by 56 · cited 2×
“47,48 These studies indicated that atomoxetine improved ADHD symptoms, but not bipolar symptoms, in children with these disorders.”
Dell'Agnello, G., Maschietto, D., Bravaccio, C., Calamoneri, F., Masi, G., Curatolo, P., Besana, D., Mancini, F., Rossi, A., Poole, L., et al. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.07.008 · Cited by 54
Hah, M., & Chang, K. (2005) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2005.15.996 · Cited by 48
Brewerton, T. D., & Duncan, A. E. (2016) · European Eating Disorders Review · doi:10.1002/erv.2468 · Cited by 37
Charnsil, C. (2011) · Journal of Attention Disorders · doi:10.1177/1087054710376907 · Cited by 36
Bushe, C., Day, K., Reed, V., Karlsdotter, K., Berggren, L., Pitcher, A., Televantou, F., & Haynes, V. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116636105 · Cited by 31 · cited 3×
“28,39,40 42 Data from recent longer-term studies that incorporate current ADHD trial design concepts also show that there is equivalent efficacy for atomoxetine and methylphenidate, both in adults and children, 43,44 including data from the most recent updated network meta-analysis.”
Self-citationGabriel, A., & Violato, C. (2011) · ADHD Attention Deficit and Hyperactivity Disorders · doi:10.1007/s12402-011-0063-1 · Cited by 30
Shaywitz, B. A., Williams, D. W., Fox, B. K., & Wietecha, L. A. (2014) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2013.0148 · Cited by 18
Cited by
Fu, D., Wu, D.-D., Guo, H.-L., Hu, Y.-H., Xia, Y., Ji, X., Fang, W.-R., Li, Y.-M., Xu, J., Chen, F., et al. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.780921 · Cited by 66
Adult ADHD and comorbid anxiety and depressive disorders: a review of etiology and treatment
Fu, X., Wu, W., Wu, Y., Liu, X., Liang, W., Wu, R., & Li, Y. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1597559 · Cited by 54
Iwanami, A., Saito, K., Fujiwara, M., Okutsu, D., & Ichikawa, H. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19m12979 · Cited by 44
Khoodoruth, M. A. S., Ouanes, S., & Khan, Y. S. (2022) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2022.104275 · Cited by 39
Managing Adult Attention-Deficit/Hyperactivity Disorder With Comorbid Substance Use Disorder
Ward, B., Bahji, A., & Crockford, D. (2022) · Canadian Journal of Addiction · doi:10.1097/cxa.0000000000000160 · Cited by 3
Metadata
- Authors
- Clemow, D., Bushe, C., Mancini, M., Ossipov, M., & Upadhyaya, H.
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2017-02
- Volume
- Volume 13
- Pages
- 357-371
- ISSN
- 1176-6328 (ISSN-L)
- 1178-2021
- OpenAlex
- W2587631464
- Cited by
- 58
- References
- 43
- FWCI
- 3.79
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.